Across TCGA pan-cancer cohorts, RNU6-616P RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RNU6-616P data layer.
The strongest signal is observed in thyroid carcinoma (THCA), where higher RNU6-616P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-616P expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.
THCA, COAD, and KIRP are the cancer types where RNU6-616P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.